Pretreatment platelet count improves the prognostic performance of the TNM staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: a single-institutional study of 2,626 patients

Table 2 Multivariate analyses of prognostic factors for patients with early-stage and locoregionally advanced NPC

Endpoint	Variable ^a	HR	95% CI	P value
Early-stage NPC ( n = 1,057)
Overall survival	Age (>45 vs. ≤45 years)	1.586	1.213–2.075	0.001
	Sex (female vs. male)	1.409	1.019–1.949	0.038
	T category (T2 vs. T1)	1.352	1.014–1.803	0.040
	N category (N1 vs. N0)	2.326	1.732–3.124	<0.001
	PLT count (>300 × 10⁹/L vs. ≤300 × 10⁹/L)	2.057	1.510–2.804	<0.001
Locoregional recurrence–free survival	N category (N1 vs. N0)	1.566	1.053–2.328	0.027
Distant metastasis–free survival	Age (>45 vs. ≤45 years)	1.387	0.970–1.984	0.073
	T category (T2 vs. T1)	1.899	1.249–2.888	0.003
	N category (N1–3 vs. N0)	2.532	1.677–3.824	<0.001
	PLT count (>300 × 10⁹/L vs. ≤300 × 10⁹/L)	1.788	1.167–2.739	0.008
Locoregionally advanced NPC ( n = 1,569)
Overall survival	Age (>45 vs. ≤45 years)	1.657	1.397–1.966	<0.001
	Gender (female vs. male)	1.452	1.163–1.813	0.001
	PLT count (>300 × 10⁹/L vs. ≤300 × 10⁹/L)	1.716	1.407–2.093	<0.001
Locoregional recurrence–free survival	Age (>45 vs. ≤45 years)	1.541	1.238–2.037	<0.001
Locoregional recurrence–free survival	Gender (female vs. male)	1.561	1.259–1.888	0.001
Distant metastasis–free survival	N category (N1–3 vs. N0)	2.014	1.331–3.047	0.001
Distant metastasis–free survival	PLT count (>300 × 10⁹/L vs. ≤300 × 10⁹/L)	1.859	1.393–2.481	<0.001

^aThe parameters listed in this column were included in the multivariate analysis using Cox proportional hazards model by backward elimination. PLT, platelet; CRT, chemoradiotherapy; RT, radiotherapy; HR, hazard ratio; CI, confidence interval.

ISSN: 2523-3548